In studies without combination ACT, arming adenovirus and vaccinia vectors with TNF receptor superfamily ligands including OX40L, 4-1BBL, and GITRL led to enhanced anti-tumour effects [133–135]. The gene discussed is TNFSF18; the disease is neoplasm.